Edgewise Announces Positive 2-Month Interim Results from Open Label Study of EDG-5506 in Adults with Becker
Edgewise Therapeutics has announced 2-month interim results from the ongoing ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy. Results showed that EDG-5506 significantly lowered muscle damage biomarkers in adults with Becker,…Learn More